Aethlon Medical, Inc. (NASDAQ: AEMD) reported that patients in the second cohort of its Australian oncology feasibility study showed biological ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE